Pharnext raises funds to test first Pleodrug in the clinic
This article was originally published in Scrip
Executive Summary
Pharnext has raised €4.8 million in a series A financing that will be used to test its first Pleodrug in the clinic by the end of this year, for the treatment of the serious neuromuscular condition Charcot-Marie-Tooth disease.